You are here: Industry Insights > biosimilars

News List

A Review of Oncology Biosimilars Products and Companies David Orchard-Webb
May 12, 2022
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
Biosimilars 2020: Low Approvals, but Significant Advances Neeta Ratanghayra
March 18, 2021
2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
2022 — a turning point for US biosimilars? CPhIonline
February 10, 2022
Cardinal Health says the majority of healthcare providers are keen to use biosimilars despite current market challenges.
Biologics CDMO market to double in value by 2026, suggests report europeanpharmaceuticalreview
April 16, 2021
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
Global Biosimilars Market Poised to Grow at Chart-topping Levels with a CAGR of 17.3%, Reaching $79.2 Billion by 2026 prnasia
December 11, 2020
Frost & Sullivan's recent analysis, Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026, finds that the cost-benefit for end-users (patients) and ease of partnering with specialty contract development and ...
Biocon Biologics gets Rs 1, 125 cr capital injection from Goldman Sachs expresspharma
November 09, 2020
Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion.
A Comparison of the Biosimilar Accessibility in China, the EU, and the U.S.: China’s Biosimilars Commercialized at an Impressive Speed PharmaSources/1°C
February 04, 2020
Biosimilars significantly reduce patients’ burden and boost the life science innovation to benefit more people!
Celltrion, Nan Fung Group form JV to market Biosimilars in China biospectrumasia
July 20, 2019
Vcell Healthcare Limited will obtain the exclusive rights in mainland China to develop, manufacture and commercialize three US FDA and EMA approved biosimilar products from Celltrion
British Columbia first province to switch patients to biosimilars europeanpharmaceuticalreview
May 31, 2019
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
Surge of Indian biosimilars market forecast in 2019 cphi-online
April 26, 2019
India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Previous page 1 2 3 4 5 6 Next page